Free Trial
ASX:IVX

Invion (IVX) Stock Price, News & Analysis

Invion logo

About Invion Stock (ASX:IVX)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
471,000 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, anogenital, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Receive IVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invion and its competitors with MarketBeat's FREE daily newsletter.

IVX Stock News Headlines

Ticking time bomb. Detonation Nov 5
Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late.
Invion Ltd. Issues 50 Million New Shares on ASX
Invion Expands Share Issuance and Eyes Technology Rights
See More Headlines

IVX Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Invion investors own include Denbury Resources (DNR), Walt Disney (DIS), Carlisle Companies (CSL), Cyclone Metals Limited (CFE.AX) (CFE), Camtek (CAMT), Boston Properties (BXP) and BioSpecifics Technologies (BSTC).

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-5,630,000.00
Net Margins
-152.34%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.69 million

Miscellaneous

Outstanding Shares
6,770,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
1.12
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (ASX:IVX) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners